폐성숙주사 (Antenatal Corticosteroid) - 의학 (Medicine)

문서의 이전 판을 선택했습니다! 저장하면 이 자료로 새 판을 만듭니다.

{{tag>antenatal corticosteroid}}
{{page>:틀#의학}}
======폐성숙주사 (Antenatal Corticosteroid) ======
 
/* 요기에 본문을 적으시와용 */

폐성숙주사(스테로이드)는 조산 시 폐가 완전히 형성되지 않아 자가 호흡이 어려운 아기들이 호흡할 수 있도록 돕는 주사다.

all women between 24 and 34 weeks of gestation who are at risk of preterm birth within 7 days

* betamethasone 12 mg IM 24시간 간격
  * dexamethasone 6 mg IM 4회 12 시간 간격

WHO recommends that a single repeat course of steroids may be considered if preterm birth does not occur within 7 days after the initial course and subsequent assessment demonstrates that there is a high risk of preterm birth in the next 7 days

[[https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/antenatal-corticosteroid-therapy-for-fetal-maturation|참고]]

=====기타=====

====양막파수====

32주 까지만...

• ACS therapy is indicated in women with PROM from
24 to 32 weeks’ gestation not presenting clinical signs
of chorioamnionitis.

This scenario includes considerable risk of infection for
the mother and the fetus. The evidence justifying the use
of ACS in PROM is based on two major meta-analyses:
In the 2006 Cochrane Review w37x ‘‘ACS are shown to
be beneficial in the subgroup of infants whose mothers
have PROM. Neonatal death, RDS, IVH, NEC, and duration of respiratory support are all reduced, without an
increase in either maternal or neonatal infection’’. Similar
results were obtained from Harding et al.’s meta-analysis
in 2001 w17x. Beyond 32 weeks of gestation, the risk of
chorioamnionitis is higher than the risks derived from
prematurity w15, 24x.

2+1? 이 필드는 비어 있도록 유지하세요:

편집 요약

참고: 이 문서를 편집하면 내용은 다음 라이선스에 따라 배포하는 데 동의하는 것으로 간주합니다: CC Attribution-Noncommercial-Share Alike 4.0 International

연결문서